# Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients

## TL;DR

Combining irreversible electroporation with allogeneic gamma delta T cells improves survival in locally advanced pancreatic cancer patients.

## Contribution

This study demonstrates that combining IRE with allogeneic γδ T-cell therapy improves survival outcomes in LAPC patients.

## Key findings

- Group A patients receiving IRE plus γδ T-cell therapy had longer median OS (14.5 months) compared to group B (11 months).
- Patients receiving multiple γδ T-cell infusions had even longer OS (17 months) than those with a single infusion (13.5 months).
- IRE combined with allogeneic γδ T-cell infusion is a promising strategy for enhancing antitumor efficacy in LAPC.

## Abstract

Immunotherapy has limited efficacy against locally advanced pancreatic cancer (LAPC) due to the presence of an immunosuppressive microenvironment (ISM). Irreversible electroporation (IRE) can not only induce immunogenic cell death, but also alleviate immunosuppression. This study aimed to investigate the antitumor efficacy of IRE plus allogeneic γδ T cells in LAPC patients. A total of 62 patients who met the eligibility criteria were enrolled in this trial, then randomized into two groups (A: n = 30 and B: n = 32). All patients received IRE therapy and after receiving IRE, the group A patients received at least two cycles of γδ T-cell infusion as one course continuously. Group A patients had better survival than group B patients (median OS: 14.5 months vs. 11 months; median PFS: 11 months vs. 8.5 months). Moreover, the group A patients treated with multiple courses of γδ T-cell infusion had longer OS (17 months) than those who received a single course (13.5 months). IRE combined with allogeneic γδ T-cell infusion is a promising strategy to enhance the antitumor efficacy in LAPC patients, yielding extended survival benefits.

ClinicalTrials.gov ID: NCT03180437.